Longeveron Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
Longeveron Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Allogeneic MSC in Mild Alzheimer's Disease (Phase 2) using Cell Therapy.
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| NEWS & MEDIA | Alzheimer | Cell Therapy | n/a | Public pipeline row |
| Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | Frailty | Antibiotic | Phase 1 | Phase 2 | Public pipeline row |
| Longeveron Mesenchymal Stem Cells (LMSCs) | Aging Frailty | Vaccine | Phase 1 | Phase 2 | Public pipeline row |
| Allo-hMSCs | Hypoplastic Left Heart Syndrome | n/a | Phase 1 | Public pipeline row |
| Allogeneic MSC | Mild Alzheimer's Disease | n/a | Phase 2 | Public pipeline row |
| Lomecel-B medicinal signaling cells | Hypoplastic Left Heart Syndrome | n/a | Phase 2 | Public pipeline row |
Estimated cash runway: Runway 6-12 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT02398604 | Phase 1 | TERMINATED | 5 | 2019-03 |
| NCT02065245 | Phase 1 | Phase 2 | COMPLETED | 65 | 2019-10-02 |
| NCT02982915 | Phase 1 | Phase 2 | COMPLETED | 62 | 2021-09 |
| NCT05233774 | Phase 2 | COMPLETED | 50 | 2023-09-29 |
| NCT04925024 | Phase 2 | ACTIVE_NOT_RECRUITING | 40 | 2026-06-30 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.